- Recommended dose for CYP2D6 EMs: 84 mg PO bid, with or without food
- Recommended dose for CYP2D6 IMs: 84 mg PO bid, with or without food
- Recommended dose for CYP2D6 PMs: 84 mg PO qd, with or without food
- CYP2D6 EMs and IMs: Reduce dose to 84 mg PO qd if coadministered with strong (e.g., paroxetine) or moderate (e.g., terbinafine) CYP2D6 inhibitor
- CYP2D6 EMs: Reduce dose to 84 mg PO qd if coadministered with strong (e.g. ketoconazole) or moderate (e.g., fluconazole) CYP3A inhibitors
- |
Note:
|Select patients based on their CYP2D6 metabolizer status - Establish patient's CYP2D6 genotypes using an FDA-cleared test
- A specific dosage cannot be recommended for those patients whose CYP2D6 genotype cannot be determined (i.e., IMs)
- Patients who are CYP2D6 ultra-rapid metabolizers (URMs) may not achieve adequate concentrations of eliglustat to achieve a therapeutic effect
- In patients switching from Enzyme Replacement Therapy (ERT) to eliglustat, administer eliglustat 24 hours after the last dose of the previous ERT
- Avoid consumption of grapefruit (a strong CYP3A inhibitor) or its juice
- If a dose of is missed, take the prescribed dose at the next scheduled time; do not double the next dose
- Safety and effectiveness in pediatric patients have not been established
